| Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide SR McCurdy, JA Kanakry, MM Showel, HL Tsai, J Bolaños-Meade, ... Blood, The Journal of the American Society of Hematology 125 (19), 3024-3031, 2015 | 301 | 2015 |
| Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia RJ Kreitman, C Dearden, PL Zinzani, J Delgado, L Karlin, T Robak, ... Leukemia 32 (8), 1768-1777, 2018 | 250 | 2018 |
| Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults YL Kasamon, J Bolaños-Meade, GT Prince, HL Tsai, SR McCurdy, ... Journal of Clinical Oncology 33 (28), 3152, 2015 | 249 | 2015 |
| Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS CG Kanakry, HL Tsai, J Bolaños-Meade, BD Smith, I Gojo, JA Kanakry, ... Blood, The Journal of the American Society of Hematology 124 (25), 3817-3827, 2014 | 198 | 2014 |
| Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide SR McCurdy, YL Kasamon, CG Kanakry, J Bolaños-Meade, HL Tsai, ... Haematologica 102 (2), 391, 2017 | 175 | 2017 |
| The importance of IGHV mutational status in del (11q) and del (17p) chronic lymphocytic leukemia DE Gladstone, A Blackford, E Cho, L Swinnen, Y Kasamon, CD Gocke, ... Clinical Lymphoma Myeloma and Leukemia 12 (2), 132-137, 2012 | 156 | 2012 |
| A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039) S Ansell, ME Gutierrez, MA Shipp, D Gladstone, A Moskowitz, I Borello, ... Blood 128 (22), 183, 2016 | 153 | 2016 |
| High-dose cyclophosphamide without stem-cell rescue for refractory CIDP TH Brannagan III, A Pradhan, T Heiman-Patterson, AC Winkelman, ... Neurology 58 (12), 1856-1858, 2002 | 149 | 2002 |
| Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias JE Karp, BM Thomas, JM Greer, C Sorge, SD Gore, KW Pratz, BD Smith, ... Clinical Cancer Research 18 (24), 6723-6731, 2012 | 134 | 2012 |
| Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies DE Gladstone, AA Zachary, EJ Fuchs, L Luznik, YL Kasamon, KE King, ... Biology of Blood and Marrow Transplantation 19 (4), 647-652, 2013 | 129 | 2013 |
| HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation AM Zeidan, PM Forde, H Symons, A Chen, BD Smith, K Pratz, H Carraway, ... Biology of Blood and Marrow Transplantation 20 (3), 314-318, 2014 | 125 | 2014 |
| Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a … J Bolaños-Meade, KR Cooke, CJ Gamper, SA Ali, RF Ambinder, ... The Lancet Haematology 6 (4), e183-e193, 2019 | 122 | 2019 |
| Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host … JA Kanakry, YL Kasamon, J Bolaños-Meade, IM Borrello, RA Brodsky, ... Biology of Blood and Marrow Transplantation 19 (10), 1514-1517, 2013 | 114 | 2013 |
| Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide AE DeZern, ML Zahurak, HJ Symons, KR Cooke, GL Rosner, ... Blood Advances 4 (8), 1770-1779, 2020 | 110 | 2020 |
| Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma JA Kanakry, YL Kasamon, CD Gocke, HL Tsai, J Davis-Sproul, N Ghosh, ... Biology of Blood and Marrow Transplantation 19 (4), 602-606, 2013 | 102 | 2013 |
| Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma YL Kasamon, HA Jacene, CD Gocke, LJ Swinnen, DE Gladstone, ... Blood, The Journal of the American Society of Hematology 119 (18), 4129-4132, 2012 | 101 | 2012 |
| Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide YL Kasamon, RF Ambinder, EJ Fuchs, M Zahurak, GL Rosner, ... Blood advances 1 (4), 288-292, 2017 | 93 | 2017 |
| Regulatory T cells for treating patients with COVID-19 and acute respiratory distress syndrome: two case reports DE Gladstone, BS Kim, K Mooney, AH Karaba, FR D'Alessio Annals of internal medicine 173 (10), 852-853, 2020 | 83 | 2020 |
| High‐dose cyclophosphamide results in long‐term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory … DE Gladstone, AA Prestrud, TH Brannagan Journal of the Peripheral Nervous System 10 (1), 11-16, 2005 | 81 | 2005 |
| Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide CG Kanakry, J Bolaños-Meade, YL Kasamon, M Zahurak, N Durakovic, ... Blood, The Journal of the American Society of Hematology 129 (10), 1389-1393, 2017 | 77 | 2017 |
